AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Study identifier:D7230C00001

ClinicalTrials.gov identifier:NCT06106945

EudraCT identifier:N/A

CTIS identifier:2023-508590-89-00

Recruiting

Official Title

A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, lmmunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants with Relapsed or Refractory Multiple Myeloma

Medical condition

Multiple Myeloma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD0305

Sex

All

Estimated Enrollment

84

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 05 Dec 2023
Estimated Primary Completion Date: 11 Nov 2025
Estimated Study Completion Date: 11 Nov 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria